Actinium Pharmaceuticals, Inc. (ATNM)
NYSEAMERICAN: ATNM · Real-Time Price · USD
1.100
+0.020 (1.85%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Actinium Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 36.47 | 48 | 72.9 | 76.68 | 108.91 | 77.83 |
Cash & Short-Term Investments | 36.47 | 48 | 72.9 | 76.68 | 108.91 | 77.83 |
Cash Growth | -39.14% | -34.16% | -4.92% | -29.60% | 39.93% | 22.45% |
Prepaid Expenses | 1.27 | 1.38 | 1.6 | 1.59 | 1.64 | 1.48 |
Restricted Cash | - | - | - | - | 0.4 | 0.39 |
Other Current Assets | - | - | - | - | - | 0.05 |
Total Current Assets | 37.74 | 49.38 | 74.51 | 78.26 | 110.94 | 79.75 |
Property, Plant & Equipment | 2.08 | 2.06 | 2.07 | 2.87 | 2.95 | 0.64 |
Other Long-Term Assets | 0.34 | 0.34 | 0.32 | 0.31 | 0.3 | - |
Total Assets | 40.16 | 51.78 | 76.9 | 81.45 | 114.19 | 80.39 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 8.51 | 7.25 | 7.57 | 7.95 | 10.13 | 5.54 |
Current Portion of Leases | 0.75 | 0.72 | 0.58 | 0.54 | 0.5 | 0.31 |
Current Unearned Revenue | - | - | - | - | - | 1 |
Total Current Liabilities | 9.26 | 7.97 | 8.15 | 8.49 | 10.63 | 6.84 |
Long-Term Leases | 0.6 | 0.97 | 0.99 | 1.57 | 2.08 | 0 |
Long-Term Unearned Revenue | - | 35 | 35 | 35 | 35 | - |
Total Liabilities | 9.86 | 43.94 | 44.14 | 45.07 | 47.71 | 6.84 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 |
Additional Paid-In Capital | 417.67 | 417.54 | 408.55 | 373.93 | 355.22 | 329.27 |
Retained Earnings | -387.33 | -409.71 | -375.83 | -337.58 | -288.77 | -255.75 |
Comprehensive Income & Other | -0.06 | -0.02 | - | - | - | - |
Shareholders' Equity | 30.3 | 7.83 | 32.76 | 36.38 | 66.48 | 73.55 |
Total Liabilities & Equity | 40.16 | 51.78 | 76.9 | 81.45 | 114.19 | 80.39 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1.34 | 1.69 | 1.57 | 2.11 | 2.58 | 0.31 |
Net Cash (Debt) | 35.13 | 46.3 | 71.33 | 74.56 | 106.33 | 77.52 |
Net Cash Growth | -40.09% | -35.09% | -4.34% | -29.87% | 37.16% | 23.39% |
Net Cash Per Share | 1.12 | 1.48 | 2.37 | 2.80 | 4.40 | 3.77 |
Filing Date Shares Outstanding | 31.44 | 31.18 | 31.2 | 29.4 | 25.73 | 22.14 |
Total Common Shares Outstanding | 31.44 | 31.2 | 31.2 | 27.63 | 25.67 | 22.14 |
Working Capital | 28.48 | 41.41 | 66.36 | 69.77 | 100.31 | 72.91 |
Book Value Per Share | 0.96 | 0.25 | 1.05 | 1.32 | 2.59 | 3.32 |
Tangible Book Value | 30.3 | 7.83 | 32.76 | 36.38 | 66.48 | 73.55 |
Tangible Book Value Per Share | 0.96 | 0.25 | 1.05 | 1.32 | 2.59 | 3.32 |
Machinery | - | 1.26 | 1.26 | 1.24 | 1.09 | 0.68 |
Construction In Progress | - | 0.1 | - | - | - | - |